Physician assistants may be more likely than dermatologists to perform unnecessary skin biopsies to check for cancer and are less likely to accurately diagnose early stage skin cancers, according to new research conducted by the University of Pittsburgh School of Medicine (UPMC).
The study examined the medical records of 33,647 skin cancer screening examinations in 20,270 unique patients who underwent screening at UPMC-affiliated dermatology offices from 2011 through 2015. The research team found that the lower detection rate among PAs was only for melanoma in situ and that PAs and dermatologists had similar detection rates for invasive melanomas and nonmelanoma skin cancers, which often are more clinically obvious.
In addition, the study found that, for every case of melanoma diagnosed, PAs needed to biopsy more than 39 pigmented lesions and dermatologists needed to biopsy slightly more than 25 such lesions. For every suspected case of melanoma, PAs’ suspicions were correct one out of every 39 times, compared to one out of 25 for dermatologists.
The study appears in JAMA Dermatology.
“Although the availability of PAs may help increase access to care and reduce waiting times for appointments, these findings have important implications for training of PAs and other non-physician practitioners in dermatology,” says lead author Laura Ferris, M.D., Ph.D., associate professor, University of Pittsburgh, Department of Dermatology, in a news release. “Currently there is no formal training or certification program in dermatology for PAs or other advanced practice providers.”
Dr. Ferris suggests that the study findings also should be considered when evaluating cost of care. PAs typically have lower salaries than physicians and health systems are increasingly shifting patient care responsibilities to such advanced practice providers in an effort to control costs.
“In the age of cost-conscious medicine, it’s important to consider more than just a clinician’s salary,” says Dr. Ferris. “Missed diagnoses or unnecessary biopsies of benign lesions should be factored into decisions about the scope of a practice, hiring decisions, supervision of providers and patient decisions about who provides their dermatologic care.”
Additional researchers on this study include Alyce M. Anderson, Ph.D., and Melissa I. Saul, M.S., of Pitt; Martha Matsumoto, M.D., of UPMC; and Aaron M. Seacrest, M.D., Ph.D., of the University of Utah.
This study was supported by National Institutes of Health grants 1TL1R001858-01 and 2P50CA121973-06.